NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: AHCL · data 2026-10-31
Anlon Healthcare Limited
In plain words
Price: 30.5% below its 52-week high of ₹37.24.
Delivery: 46.6% of traded shares were kept for delivery over the last 10 sessions, against 43.8% over the last 60.
Latest results: a net profit of ₹13 cr for the quarter ended Sept 2026 (+43.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹280 cr |
| Net profit (last 12 months) | ₹36 cr |
| Sales growth, 3 years (yearly) | 15.1% |
| Profit growth, 3 years (yearly) | 69.8% |
At a glance
Promoters 52.7% (unchanged in a year), pledged 0.0%, institutions 1.3%.
P/E 38.6, P/B 5.3, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.4%, ROCE 24.3%, operating margin 23.5%: how much profit it earns on the money it uses.
Debt/equity 0.19, Profit growth 69.8% and sales growth 15.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (18.4%).
- Healthy operating margin (23.5%).
- Profit grew 69.8% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
AHCL Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹105.61 crore, up 20.6% QoQ.
Net profit was ₹13.37 crore, up 61.5% QoQ.
Operating margin was 23.9%.
EPS was ₹0.32, up 60% QoQ.
AHCL के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹105.61 करोड़; पिछली तिमाही की तुलना में 20.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹13.37 करोड़; पिछली तिमाही की तुलना में 61.5% की बढ़त।
ऑपरेटिंग मार्जिन: 23.9%।
EPS: ₹0.32; पिछली तिमाही की तुलना में 60% की बढ़त।
AHCLના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹105.61 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 20.6% વધારો.
ચોખ્ખો નફો: ₹13.37 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 61.5% વધારો.
ઓપરેટિંગ માર્જિન: 23.9%.
EPS: ₹0.32; ગયા ક્વાર્ટરની સરખામણીએ 60% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
23/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 47.0% over the last 20 sessions vs 18.5% in the 40 before (2.54x); shares delivered per day 0.73x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 8/20: Net +₹7.29 cr bought in bulk/block deals over 90 days (0.31x a usual day's traded value); 3 net buying days, 7 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Deal ● Split ● Bonus
- 29 Oct 26Results Q2 FY27 results: net profit ₹13.4 cr +5.8% next session
- 8 Oct 26Deal Bulk deal: NEO APEX SHARE BROKING SERVICES LLP sold ₹2.29 cr -0.2% next session
- 6 Oct 26Deal Bulk deal: NEO APEX SHARE BROKING SERVICES LLP bought ₹13.18 cr -9.7% next session
- 30 Sept 26Deal Bulk deal: NEO APEX SHARE BROKING SERVICES LLP bought ₹8.69 cr -9.7% next session
- 29 Sept 26Deal Bulk deal: NEO APEX SHARE BROKING SERVICES LLP sold ₹3.64 cr -0.2% next session
- 23 Sept 26Deal Bulk deal: IRAGE BROKING SERVICES LLP sold ₹2.48 cr -0.7% next session
- 22 Sept 26Deal Bulk deal: NEO APEX SHARE BROKING SERVICES LLP sold ₹3.59 cr +13.1% next session
- 21 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED sold ₹1.4 cr +26.0% next session
- 18 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED sold ₹1.37 cr +20.1% next session
- 17 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED sold ₹0.67 cr +14.3% next session
- 16 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED bought ₹0.86 cr +8.2% next session
- 30 Jul 26Results Q1 FY27 results: net profit ₹8.3 cr -8.0% next session
- 29 May 26Results Q4 FY26 results: net profit ₹10.5 cr -4.6% next session
- 1 May 26Results Q3 FY26 results: net profit ₹5.2 cr -1.4% next session
- 24 Apr 26Split Split: face value ₹10 → ₹2 (ex-date)
- 24 Apr 26Bonus Bonus 1:1 (ex-date)
- 13 Apr 26Results Q1 FY26 results: net profit ₹3.5 cr +6.8% next session
- 9 Feb 26Results Results board meeting -1.9% next session
- 11 Nov 25Results Q2 FY26 results: net profit ₹9.3 cr -0.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹106 cr | ₹13 cr | +43.5% | 23.9% | 0.32 |
| Jun 2026 | ₹88 cr | ₹8 cr | +133.2% | 17.8% | 0.16 |
| Mar 2026 | ₹51 cr | ₹11 cr | — | 30.0% | 2.33 |
| Dec 2025 | ₹36 cr | ₹5 cr | — | 34.7% | 1.13 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 52.68% | 52.68% | 52.68% | 52.68% |
| Foreign institutions (FII) | 1.00% | 1.67% | 0.32% | 0.23% |
| Domestic institutions (DII) | 0.30% | 1.22% | 4.60% | 4.49% |
| Mutual funds | 0.00% | — | — | — |
| Retail investors | 15.01% | 11.69% | 8.95% | 7.97% |
| Number of shareholders | 81,356 | 34,671 | 12,484 | 11,412 |
Common questions
What was Anlon Healthcare Limited's latest quarterly profit?
Anlon Healthcare Limited reported a net profit of ₹13 cr for the quarter ended Sept 2026 (+43.5% on the same quarter a year earlier), on revenue of ₹106 cr.
How much do promoters hold in Anlon Healthcare Limited?
Promoters held 52.68% of Anlon Healthcare Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Anlon Healthcare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.19.
What is Anlon Healthcare Limited's P/E ratio?
About 38.6, based on the last 12 months' earnings and a price of ₹25.89 (data 2026-10-31).
What is the 52-week high and low of Anlon Healthcare Limited?
The 52-week high is ₹37.24 and the 52-week low is ₹10.37.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Anlon Healthcare Limited | ₹25.89 | ₹1,378 cr | 38.6 | 5.4 | 18.4% | 24.3% | 0.19 | +108.0% |
| NGL Fine-Chem Ltd. | ₹2,526 | ₹1,576 cr | 27.3 | — | 15.7% | 17.1% | 0.37 | +66.0% |
| Accent Microcell Limited | ₹639 | ₹1,533 cr | 26.9 | 5 | 18.7% | 22.7% | 0 | +140.2% |
| Bharat Parenterals Ltd. | ₹2,029.9 | ₹1,397 cr | 1,124.7 | 4.2 | -2.5% | -4.2% | 0.45 | +45.0% |
| TTK Healthcare Limited | ₹905.3 | ₹1,280 cr | 17.3 | — | 6% | 2.1% | 0.02 | -23.2% |
| Kopran Limited | ₹239.05 | ₹1,156 cr | 46.2 | — | 4.9% | 10.1% | 0.29 | +43.2% |
Compare AHCL with NGLFINE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AHCL in NSE Scanner →